Kelvipride-M2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glucose utilization. This synergistic combination targets multiple pathophysiological defects of type 2 diabetes, making it effective in patients inadequately controlled by diet, exercise, or monotherapy. Kelvipride-M2 Tablet PR is typically prescribed as an adjunct to lifestyle modifications to achieve optimal blood glucose levels and reduce the risk of diabetes-related complications. The extended-release formulation allows for sustained drug release, promoting better patient compliance and minimizing gastrointestinal side effects commonly associated with metformin. Patients should be monitored regularly for blood glucose levels, renal function, and potential adverse effects such as hypoglycemia, lactic acidosis, or gastrointestinal disturbances. Contraindications include severe renal impairment, metabolic acidosis, and hypersensitivity to either component. Proper dosage adjustment and adherence to prescribed regimens are essential to maximize therapeutic benefits and ensure patient safety.